网络安全检测|网络安全服务|网络安全扫描-香港墨客投资移动版

HeartStitchR, Inc. aAnd National Cardiac Research Center In Astana Announced That It Has Performed The First In Man Transapical Access Procedure on Worldwide Premier Of First In Man Trans-Apical Access Closure With Minimally Invasive HeartStitchR Technology On Two Patients

ASTANA, KAZAKHSTAN New New medical technologies in medicine have alwayshave typically come to Kazakhstan from other countries. This all changed on June 14, 2016 when Dr. Y.V. Pya and his colleagues, along with renowned British Cardiologist Dr. Michael Mullen and medical -device inventor Prof. Anthony Nobles successfully performed the new procedure successfully on 2 on two patients at the National Cardiac Research Center in Astana. The "First In Man" procedure of cardiac transapical access and closure using the Heartstitch technology was accomplished without the use of a prosthetic implant was performed in two patientshttps://kaztrk.kz/index.php/kz/a/2180

. The Both patients who were requiring replacement of their aortic heart valve received the HeartStitch® transapical procedure, allowing the team to place the Heart Valve safely into the beating heart. The patients tolerated the procedure very well and have been discharged without complication. This procedure will eventually make it possible to perform critical heart procedures percutaneously through a small puncture between the ribs rather than open heart surgery. In the years to come, this technology has the potential offor saving thousands of lives all over the world. This was also These procedures also marked the first time in Kazakhstan''s history that a medical technology was firstinitially tested in humans here first, -a technology that in part was developed in Kazakhstan, and will be built and exported to other countries.

Dr. Pya, the Chairman and CEO of the National Cardiac Research Center, comments on thised on the event: "The field of cardiac surgery inaround the world is developing toward less invasive medical care. It is much Although moreWhile more beneficial for the patient however,, it is is however much more difficult to implement at the beginningits inception. What we were able to accomplish today is a major contribution totoward achieving this goal, and it will be very welcomed by the medical community worldwide. I am very happy with our success and I thank my team and also, as well as those from HeartStitchthe HeartStitch® team, who participated in this tremendous work."

Dr. Mike Mullen, consultant cardiologist andat St. Bartholomew''s St. Barts Heart Hospital, London, and Chief Medical Officer of HeartStitch®, Inc., commented, "this exciting technology will be an important step in facilitating the next wave of technology in treating structural heart disease that will require safe, effective and simple access and closure of the ventricular apex.I believe this is the next wave of technology in treating structural heart disease. The ability to be less invasive without introducing new mechanical devices into the patient''s heart by emulating the open surgical technique is always the best way, but often the most difficult to achieve. This new technology does just that. Over the next year our task will be to refine the procedure, technology, and technique of using the device so that it may be implemented by cardiac teams performing these life saving heart operationsprocedures."

Shigeo Katsu, President of Nazarbayev University, Astana Kazakhstan commented, "HeartStitch® is an important part of the innovation directive of Nazarbayev University to broaden research out to the world. This First In Man procedure will change the lives of two Kazakh citizens, and will be the beginning of this technology helping people all over the world. I personally, am proud of student directly involved in making these successful procedures possible and look forward to further innovation as part of our international collaboration with Heartstitch® , Inc."

The road to developDeveloping and testing this new innovation which led up to this day , and the road leading up to its first use, took several years. Doctors from the National Cardiac Research Center worked side by side with engineers from HeartStitch®, Inc. a manufacturer of medical devices that works in Kazakhstan in partnership with Nazarbayev University and the National Cardiac Research Center in Kazakhstan, Los Angeles US, Zwickau Germany, and Paris France. Engineers from Heartstitch''s Kazakhstan affiliate designed parts of the final device. One of these engineers is Yerkanat Nurmakhanov, a graduate of the inaugural class of the School of Engineering of Nazarbayev University. His inventions on this and other products will become the basis for international and Kazakhstan patents.

This technology makes it possible for cardiologists to access the heart through the apex by a minimally invasive procedure. Access to the apex is then closed by using only surgical suture and not leaving a device in the heart. When widely used, this technology will make thousands of people worldwide eligible for medical treatment of their structural heart disease. With the current state of structural heart therapy, these patients have either to undergo open heart surgery or be limited to care available through the femoral vein access. On the day of the First In Man, deployment of the newly developed instrument helped to save the lives of two people in Kazakhstan, who are now on their way to recovery.